(Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter 'Shionogi') today announced the approval for INTUNIV (guanfacine hydrochloride) for the treatment of attention deficit hyperactivity disorder (ADHD) with additional indication in adult patients. Shionogi Got Approval of Additiona...
Consider dosing on an mg/kg basis. Improvements were observed starting at doses of 0.05-0.08 mg/kg once daily. Doses up to 0.12 mg/kg once daily may provide additional benefits (2.2). When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days. Which dr...